|
Poseida Therapeutics, Inc. (PSTX) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Poseida Therapeutics, Inc. (PSTX) Bundle
¿Busca evaluar el valor intrínseco de Poseida Therapeutics, Inc.? Nuestra calculadora PSTX DCF incorpora datos del mundo real junto con extensas funciones de personalización, lo que le permite refinar sus pronósticos y mejorar sus estrategias de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 130.4 | 64.7 | 72.7 | 81.8 | 91.9 | 103.3 | 116.1 |
| Revenue Growth, % | 0 | 0 | 0 | 417217.08 | -50.37 | 12.41 | 12.41 | 12.41 | 12.41 | 12.41 |
| EBITDA | -91.7 | -145.5 | -117.1 | -54.8 | -109.0 | -6.1 | -6.9 | -7.7 | -8.7 | -9.8 |
| EBITDA, % | 100 | 100 | -374748.7 | -42.02 | -168.52 | -8.4 | -8.4 | -8.4 | -8.4 | -8.4 |
| Depreciation | 1.2 | 2.6 | 4.6 | 5.2 | 5.6 | 45.5 | 51.1 | 57.5 | 64.6 | 72.6 |
| Depreciation, % | 100 | 100 | 14572 | 3.97 | 8.68 | 62.53 | 62.53 | 62.53 | 62.53 | 62.53 |
| EBIT | -92.9 | -148.1 | -121.6 | -59.9 | -114.7 | -6.7 | -7.5 | -8.5 | -9.5 | -10.7 |
| EBIT, % | 100 | 100 | -389320.7 | -45.98 | -177.2 | -9.2 | -9.2 | -9.2 | -9.2 | -9.2 |
| Total Cash | 125.3 | 309.2 | 206.3 | 282.5 | 212.2 | 72.7 | 81.8 | 91.9 | 103.3 | 116.1 |
| Total Cash, percent | .0 | .0 | .7 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | 9.1 | 9.0 | 32.1 | 36.1 | 40.6 | 45.6 | 51.3 |
| Account Receivables, % | 100 | 100 | 0 | 6.97 | 13.93 | 44.18 | 44.18 | 44.18 | 44.18 | 44.18 |
| Inventories | .0 | .0 | .0 | 4.5 | .0 | 29.6 | 33.3 | 37.4 | 42.0 | 47.2 |
| Inventories, % | 100 | 100 | 0 | 3.42 | 0 | 40.68 | 40.68 | 40.68 | 40.68 | 40.68 |
| Accounts Payable | 4.9 | .8 | 9.0 | 2.2 | 3.3 | 44.6 | 50.2 | 56.4 | 63.4 | 71.2 |
| Accounts Payable, % | 100 | 100 | 28686.22 | 1.71 | 5.05 | 61.35 | 61.35 | 61.35 | 61.35 | 61.35 |
| Capital Expenditure | -5.2 | -16.9 | -2.6 | -3.9 | -3.1 | -15.7 | -17.6 | -19.8 | -22.3 | -25.0 |
| Capital Expenditure, % | 100 | 100 | -8432.04 | -3.01 | -4.74 | -21.55 | -21.55 | -21.55 | -21.55 | -21.55 |
| Tax Rate, % | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 | -0.08676403 |
| EBITAT | -99.4 | 2,798.2 | 4,285.5 | -60.5 | -114.8 | -4.0 | -4.5 | -5.1 | -5.7 | -6.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -98.5 | 2,779.7 | 4,295.7 | -79.5 | -106.6 | 14.4 | 26.9 | 30.2 | 34.0 | 38.2 |
| WACC, % | 7.27 | 6.34 | 6.34 | 7.27 | 7.27 | 6.9 | 6.9 | 6.9 | 6.9 | 6.9 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 115.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 39 | |||||||||
| Terminal Value | 795 | |||||||||
| Present Terminal Value | 569 | |||||||||
| Enterprise Value | 684 | |||||||||
| Net Debt | 41 | |||||||||
| Equity Value | 643 | |||||||||
| Diluted Shares Outstanding, MM | 90 | |||||||||
| Equity Value Per Share | 7.13 |
What You Will Get
- Comprehensive PSTX Financials: Access to both historical and projected data for precise valuation.
- Customizable Inputs: Adjust discount rates, tax implications, revenue forecasts, and capital investments.
- Real-Time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Poseida's future growth potential.
- User-Friendly Interface: Designed for industry professionals while remaining easy for newcomers.
Key Features
- Real-Life PSTX Data: Pre-filled with Poseida Therapeutics’ historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- Step 1: Download the Excel file for Poseida Therapeutics, Inc. (PSTX).
- Step 2: Review Poseida's pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify assumptions.
- Step 5: Evaluate the outputs and leverage the results for investment strategies.
Why Choose Poseida Therapeutics, Inc. (PSTX)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Strong Pipeline: A diverse range of product candidates targeting various cancers and genetic diseases.
- Expert Team: Led by industry veterans with extensive experience in biotechnology and pharmaceuticals.
- Commitment to Quality: Rigorous research and development processes ensure high standards of safety and efficacy.
- Collaborative Partnerships: Strategic alliances with leading organizations enhance development capabilities.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for analyzing investments in Poseida Therapeutics, Inc. (PSTX).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Offer clients precise valuation insights related to Poseida Therapeutics, Inc. (PSTX).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotechnology companies like Poseida Therapeutics, Inc. (PSTX) are valued in the market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Poseida Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Poseida Therapeutics, Inc. (PSTX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.